Drug Trial Radar · NCT03694041
Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers
Last checked: Nov 20, 2026Latest source record: Mar 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
May 28, 2018
Primary completion
Mar 6, 2019
Study completion Mar 6, 2019
Sponsor
- Lead sponsor
- Aptabio Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of single ascending doses and multiple ascending doses of APX-115 in healthy males. This study also aims to evaluate the effect of food consumption on the pharmacokinetics of APX-115 and potential interaction between caffeine and APX-115 in healthy males.
Conditions
- Healthy
- Safety
Interventions
SAD: APX-115Drug
Drug: APX-115 SAD APX-115 SAD for 1day
SAD: PlaceboDrug
Drug: Placebo Placebo for 1day
MAD: APX-115Drug
Drug: APX-115 MAD APX-115 MAD repeatedly administered.
MAD: PlaceboDrug
Matching study drug will be repeatedly administered.
Food effect: fasted and fedOther
A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
Metabolic probe with or without APX-115Other
A metabolic probe will be administered with and without APX-115.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAD: incidence of treatment emergent adverse eventsTime frame: Up to Day 8
- SAD: number of clinically significant abnormal findings from vital signs (blood pressure, pulse)Time frame: Up to Day 8
- SAD: number of clinically significant abnormal findings from physical examTime frame: Up to Day 8
- SAD: number of clinically significant abnormal findings from electrocardiogramTime frame: Up to Day 8
- SAD: number of clinically significant abnormal findings from biological testsTime frame: Up to Day 8
- MAD: incidence of treatment emergent adverse eventsTime frame: Up to Day 17
- MAD: number of clinically significant abnormal findings from vital signs (blood pressure, pulse)Time frame: Up to Day 17
- MAD: number of clinically significant abnormal findings from physical examsTime frame: Up to Day 17
- MAD: number of clinically significant abnormal findings from electrocardiogramTime frame: Up to Day 17
- Food effect: peak serum concentration (Cmax) of APX-115 under fasting and fed conditionsTime frame: Up to Day 4 post-dose
- Food effect: time to reach the Cmax (Tmax) of APX-115 under fasting and fed conditionsTime frame: Up to Day 4 post-dose
- Food effect: area under the curve (AUC) of APX-115 under fasting and fed conditionsTime frame: Up to Day 4 post-dose
- Food effect: elimination rate constant (Kel) of APX-115 under fasting and fed conditionsTime frame: Up to Day 4 post-dose
- Food effect: ratio AUCfed/AUCfastedTime frame: Up to Day 4 post-dose
- Drug interaction: peak serum concentration (Cmax) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
- Drug interaction: Time to reach the Cmax (tmax) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
- Drug interaction study: Area under the Curve (AUC) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
- Drug interaction: elimination rate constant (Kel) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
- Drug interaction: half-life (t1/2) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
- Drug interaction: volume of distribution (Vd/f) of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
- Drug interaction: clearance of a metabolic probe or APX-115Time frame: Up to Day 4 post-dose
- Drug interaction: Incidences of treatment emergent adverse eventsTime frame: Up to Day 4 post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eurofins Optimed
Gières, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.